Company: Novo Nordisk
2007 Sales: $5.8 billion
Market share: 7.8%
CAGR: 17.6%
What they have: Denmark-based Novo Nordisk's only blockbuster is NovoRapid, a fast-acting insulin product.
What to look for: Novo Nordisk has three experimental treatments awaiting FDA approval. NovoMix is a Type 1 and 2 diabetes treatment, and Activelle is a low-dose hormone replacement therapy. Novo's most anticipated new therapy is the anti-diabetic drug Liraglutide. Liraglutide, which is a new class of antidiabetic medications called GLP-1 analogues, improved glucose control in late-stage clinical studies. The drug is also in Phase II testing for obesity.
Links:
[1] http://www.fiercebiotech.com/special-reports/johnson-johnson-biotech-marketshare-report
[2] http://www.fiercebiotech.com/special-reports/biotech-marketshare-report
[3] http://www.fiercebiotech.com/special-reports/eli-lilly-biotech-marketshare-report